vs
Amphastar Pharmaceuticals, Inc.（AMPH）与百胜餐饮集团（LCUT）财务数据对比。点击上方公司名可切换其他公司
百胜餐饮集团的季度营收约是Amphastar Pharmaceuticals, Inc.的1.1倍（$204.1M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 8.9%，领先4.4%），Amphastar Pharmaceuticals, Inc.同比增速更快（-1.8% vs -5.2%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $2.6M），过去两年百胜餐饮集团的营收复合增速更高（19.8% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
百胜餐饮集团是美国跨国快餐企业，1977年百事可乐收购肯德基、必胜客、塔可Bell后将其整合为旗下子公司，1997年百事剥离该业务板块后正式独立为百胜集团。集团目前运营肯德基、必胜客、塔可Bell、哈比特汉堡等多个餐饮品牌，同时布局相关餐饮科技业务，门店网络遍布全球多个国家和地区。
AMPH vs LCUT — 直观对比
营收规模更大
LCUT
是对方的1.1倍
$183.1M
营收增速更快
AMPH
高出3.3%
-5.2%
净利率更高
AMPH
高出4.4%
8.9%
自由现金流更多
AMPH
多$22.0M
$2.6M
两年增速更快
LCUT
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $204.1M |
| 净利润 | $24.4M | $18.2M |
| 毛利率 | 46.8% | 38.6% |
| 营业利润率 | 19.4% | 9.8% |
| 净利率 | 13.3% | 8.9% |
| 营收同比 | -1.8% | -5.2% |
| 净利润同比 | -35.7% | 103.5% |
| 每股收益（稀释后） | $0.51 | $0.83 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHLCUT
| Q4 25 | $183.1M | $204.1M | ||
| Q3 25 | $191.8M | $171.9M | ||
| Q2 25 | $174.4M | $131.9M | ||
| Q1 25 | $170.5M | $140.1M | ||
| Q4 24 | $186.5M | $215.2M | ||
| Q3 24 | $191.2M | $183.8M | ||
| Q2 24 | $182.4M | $141.7M | ||
| Q1 24 | $171.8M | $142.2M |
净利润AMPHLCUT
| Q4 25 | $24.4M | $18.2M | ||
| Q3 25 | $17.4M | $-1.2M | ||
| Q2 25 | $31.0M | $-39.7M | ||
| Q1 25 | $25.3M | $-4.2M | ||
| Q4 24 | $38.0M | $8.9M | ||
| Q3 24 | $40.4M | $344.0K | ||
| Q2 24 | $37.9M | $-18.2M | ||
| Q1 24 | $43.2M | $-6.3M |
毛利率AMPHLCUT
| Q4 25 | 46.8% | 38.6% | ||
| Q3 25 | 51.4% | 35.1% | ||
| Q2 25 | 49.6% | 38.6% | ||
| Q1 25 | 50.0% | 36.1% | ||
| Q4 24 | 46.5% | 37.7% | ||
| Q3 24 | 53.3% | 36.7% | ||
| Q2 24 | 52.2% | 38.5% | ||
| Q1 24 | 52.4% | 40.5% |
营业利润率AMPHLCUT
| Q4 25 | 19.4% | 9.8% | ||
| Q3 25 | 13.2% | 3.9% | ||
| Q2 25 | 24.2% | -28.2% | ||
| Q1 25 | 21.9% | 0.8% | ||
| Q4 24 | 24.2% | 7.2% | ||
| Q3 24 | 29.8% | 4.7% | ||
| Q2 24 | 30.3% | 0.8% | ||
| Q1 24 | 27.9% | 1.3% |
净利率AMPHLCUT
| Q4 25 | 13.3% | 8.9% | ||
| Q3 25 | 9.0% | -0.7% | ||
| Q2 25 | 17.8% | -30.1% | ||
| Q1 25 | 14.8% | -3.0% | ||
| Q4 24 | 20.4% | 4.1% | ||
| Q3 24 | 21.1% | 0.2% | ||
| Q2 24 | 20.8% | -12.8% | ||
| Q1 24 | 25.1% | -4.4% |
每股收益（稀释后）AMPHLCUT
| Q4 25 | $0.51 | $0.83 | ||
| Q3 25 | $0.37 | $-0.05 | ||
| Q2 25 | $0.64 | $-1.83 | ||
| Q1 25 | $0.51 | $-0.19 | ||
| Q4 24 | $0.74 | $0.41 | ||
| Q3 24 | $0.78 | $0.02 | ||
| Q2 24 | $0.73 | $-0.85 | ||
| Q1 24 | $0.81 | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $4.3M |
| 总债务越低越好 | $608.7M | $135.0M |
| 股东权益账面价值 | $788.8M | $202.3M |
| 总资产 | $1.6B | $572.6M |
| 负债/权益比越低杠杆越低 | 0.77× | 0.67× |
8季度趋势，按日历期对齐
现金及短期投资AMPHLCUT
| Q4 25 | $282.8M | $4.3M | ||
| Q3 25 | $276.2M | $12.1M | ||
| Q2 25 | $231.8M | $12.0M | ||
| Q1 25 | $236.9M | $10.4M | ||
| Q4 24 | $221.6M | $2.9M | ||
| Q3 24 | $250.5M | $6.0M | ||
| Q2 24 | $217.8M | $3.4M | ||
| Q1 24 | $289.6M | $4.6M |
总债务AMPHLCUT
| Q4 25 | $608.7M | $135.0M | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $142.5M | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHLCUT
| Q4 25 | $788.8M | $202.3M | ||
| Q3 25 | $776.7M | $184.6M | ||
| Q2 25 | $757.5M | $185.8M | ||
| Q1 25 | $751.3M | $225.7M | ||
| Q4 24 | $732.3M | $229.9M | ||
| Q3 24 | $727.7M | $220.9M | ||
| Q2 24 | $713.3M | $219.8M | ||
| Q1 24 | $672.4M | $223.7M |
总资产AMPHLCUT
| Q4 25 | $1.6B | $572.6M | ||
| Q3 25 | $1.7B | $581.1M | ||
| Q2 25 | $1.6B | $551.9M | ||
| Q1 25 | $1.6B | $594.6M | ||
| Q4 24 | $1.6B | $634.3M | ||
| Q3 24 | $1.5B | $668.7M | ||
| Q2 24 | $1.5B | $617.0M | ||
| Q1 24 | $1.6B | $602.7M |
负债/权益比AMPHLCUT
| Q4 25 | 0.77× | 0.67× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 0.62× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $3.7M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $2.6M |
| 自由现金流率自由现金流/营收 | 13.4% | 1.3% |
| 资本支出强度资本支出/营收 | 4.5% | 0.6% |
| 现金转化率经营现金流/净利润 | 1.35× | 0.21× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $3.3M |
8季度趋势，按日历期对齐
经营现金流AMPHLCUT
| Q4 25 | $32.9M | $3.7M | ||
| Q3 25 | $52.6M | $-22.2M | ||
| Q2 25 | $35.6M | $9.3M | ||
| Q1 25 | $35.1M | $16.7M | ||
| Q4 24 | $29.0M | $20.3M | ||
| Q3 24 | $60.0M | $-22.7M | ||
| Q2 24 | $69.1M | $10.4M | ||
| Q1 24 | $55.3M | $10.5M |
自由现金流AMPHLCUT
| Q4 25 | $24.6M | $2.6M | ||
| Q3 25 | $47.2M | $-22.7M | ||
| Q2 25 | $25.0M | $8.2M | ||
| Q1 25 | $24.4M | $15.1M | ||
| Q4 24 | $16.6M | $19.7M | ||
| Q3 24 | $46.2M | $-23.2M | ||
| Q2 24 | $63.1M | $9.9M | ||
| Q1 24 | $46.5M | $9.9M |
自由现金流率AMPHLCUT
| Q4 25 | 13.4% | 1.3% | ||
| Q3 25 | 24.6% | -13.2% | ||
| Q2 25 | 14.3% | 6.2% | ||
| Q1 25 | 14.3% | 10.8% | ||
| Q4 24 | 8.9% | 9.1% | ||
| Q3 24 | 24.1% | -12.6% | ||
| Q2 24 | 34.6% | 7.0% | ||
| Q1 24 | 27.1% | 7.0% |
资本支出强度AMPHLCUT
| Q4 25 | 4.5% | 0.6% | ||
| Q3 25 | 2.8% | 0.3% | ||
| Q2 25 | 6.1% | 0.9% | ||
| Q1 25 | 6.3% | 1.1% | ||
| Q4 24 | 6.7% | 0.3% | ||
| Q3 24 | 7.2% | 0.3% | ||
| Q2 24 | 3.3% | 0.4% | ||
| Q1 24 | 5.1% | 0.4% |
现金转化率AMPHLCUT
| Q4 25 | 1.35× | 0.21× | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | 2.28× | ||
| Q3 24 | 1.48× | -65.89× | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
LCUT
| Kitchenware | $114.3M | 56% |
| Tableware | $41.7M | 20% |
| Home Solutions | $29.4M | 14% |
| Other | $18.8M | 9% |
